

Morphine Attenuated the Cytotoxicity Induced by Arsenic Trioxide in H9c2 Cardiomyocytes

Hossein Amini-Khoei^{1,2} · Mir-Jamal Hosseini³ · Majid Momeny⁴ ·
Maryam Rahimi-Balaei⁵ · Shayan Amiri^{1,2} · Arya Haj-Mirzaian^{1,2} · Mostafa Khedri⁶ ·
Samane Jahanabadi^{1,2} · Ali Mohammadi-Asl^{1,2} · Shahram Ejtemaie Mehr^{1,2} ·
Ahmad Reza Dehpour^{1,2}

Received: 19 December 2015 / Accepted: 20 January 2016 / Published online: 27 January 2016
© Springer Science+Business Media New York 2016

Abstract Arsenic trioxide (ATO) is an efficient drug for the treatment of the patients with acute promyelocytic leukemia (APL). Inhibition of proliferation as well as apoptosis, attenuation of migration, and induction of differentiation in tumor cells are the main mechanisms through which ATO acts against APL. Despite advantages of ATO in treatment of some malignancies, certain harmful side effects, such as cardiotoxicity, have been reported. It has been well documented that morphine has antioxidant, anti-apoptotic, and cytoprotective properties and is able to attenuate cytotoxicity. Therefore, in this study, we aimed to investigate the protective effects of morphine against ATO toxicity in H9c2 myocytes using multi-parametric assay including thiazolyl blue tetrazolium bromide (MTT) assay, reactive oxygen species (ROS)

generation, caspase 3 activity, nuclear factor kappa B (NF- κ B) phosphorylation assay, and expression of apoptotic markers. Our results showed that morphine (1 μ M) attenuated cytotoxicity induced by ATO in H9c2 cells. Results of this study suggest that morphine may have protective properties in management of cardiac toxicity in patients who receive ATO as an anti-cancer treatment.

Keywords Arsenic trioxide · Morphine · Cardiomyocyte · Cytotoxicity · H9c2

Introduction

Arsenic trioxide (ATO), as Chinese traditional medicine, is an efficient therapeutic agent used in acute promyelocytic leukemia (APL) and different types of human malignancies including renal cell carcinoma, small-cell lung carcinoma, cervical cancer, hepatocellular carcinoma, breast cancer, fibrosarcoma, and neuroblastoma [1–3]. A growing body of evidence indicates that mechanisms of action of ATO against malignant cells may be related to activation of apoptosis signaling such as pro-caspases [4], down-regulation of anti-apoptotic proteins like Bcl-2 [5], inducing DNA damage [6], mitochondrial membrane potential collapse, and increasing the reactive oxygen species (ROS) formation [7–9]. Moreover, it has been shown that ATO stimulates expression of apoptotic genes such as p53-up-regulated modulator of apoptosis (*PUMA*) and Bcl-2-associated *X* protein (*BAX*) [10, 11]. Our previous study suggested that ATO induces apoptosis in an APL cell line via up-regulation of p73 through suppression of nuclear factor kappa B (NF- κ B) which plays a key role in cell survival via increased expression of anti-apoptotic genes such as *survivin* [12–14], *X*-linked inhibitor of apoptosis protein (*X-IAP*), cellular inhibitor of apoptosis proteins (*cIAP1* and *cIAP2*) [15],

Hossein Amini-Khoei and Mir-Jamal Hosseini contributed equally to this work.

✉ Ahmad Reza Dehpour
dehpour@yahoo.com

¹ Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

² Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran

³ Department of Pharmacology and Toxicology, Faculty of Pharmacy, Zanjan University of Medical Sciences, Tehran, Iran

⁴ Department of Molecular Pathology, University of Queensland, Center for Clinical Research, Brisbane, QLD, Australia

⁵ Department of Human Anatomy and Cell Science, College of Medicine, Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada

⁶ Department of Immunology, Immunology Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

and *BCL2*-like 1 (*BCL-XL*) [16] as well as increasing the lactate dehydrogenase (LDH) leakage [6].

Despite advantages of ATO in treatment of several types of malignancies, certain lethal and toxic side effects at therapeutic doses have been reported such as sudden death [17], hepatotoxicity [18], and also cardiotoxicity, which is manifested by QTc prolongation and T-wave inversion and heart block [19–21]. Also, recent evidence suggests that mitochondrial dysfunction plays a critical role in ATO-mediated cardiotoxicity via increasing ROS production [22, 23]. Therefore, poly-therapy for mitigating the ATO-induced cardiotoxicity seems a necessity based on aforementioned studies. In the current study, we investigated possible protective effects of morphine against ATO-induced cardiotoxicity in H9c2 cardiac muscle cells.

Material and Methods

Cell Line and Treatment

H9c2 cells were purchased from National Cell Bank of Iran (NCBI; Tehran, Iran) and maintained in Dulbecco's modified Eagle's medium (DMEM), containing 0.15 % sodium bicarbonate, 10 % fetal bovine serum (Invitrogen), 0.11 % sodium pyruvate, 0.45 % glucose, 20 μ M L-glutamine, 50 μ g/ml gentamicin sulfate, 100 IU/ml penicillin, 10 μ g/ml streptomycin, and 25 ng/ml amphotericin B, without phenol red. Cells were grown in 75-cm² tissue culture flasks at 37 °C in a 5 % CO₂ humidified incubator. H9c2 cells were treated with 0.5, 1, and 2 μ M of ATO (Sina Darou, Tehran, Iran). An appropriate amount of stock solution (0.5 mM in DMEM) of ATO was added to culture medium to obtain the desired concentrations and then incubated for 24, 48, and 72 h. The H9c2 cells were exposed to 1 μ M of morphine (Mac Farland & Smith, England) 4 h before ATO treatment and incubated for 24, 48, and 72 h.

Thiazolyl Blue Tetrazolium Bromide Assay

The inhibitory effects of ATO on growth and proliferation of H9c2 cells were investigated by uptake of thiazolyl blue tetrazolium bromide (MTT) by the living cells as described by Momeny et al. [12] in 96-well plates (SPL Lifesciences, Pocheon, Korea) at a concentration of 5000 cells/100 μ l/well.

Bromodeoxyuridine Cell Proliferation Assay

The effects of ATO and morphine on DNA synthesis in the H9c2 cells were studied using a colorimetric bromodeoxyuridine (BrdU)-based cell proliferation enzyme-linked immunosorbent assay (ELISA) kit (Roche Molecular Biochemicals, Mannheim, Germany) at 450 nm in different time intervals (24, 48, and 72 h) according to the manufacturer's instructions.

Measurement of ROS Formation

The rate of ROS formation was assayed by fluorescence spectrophotometer (FLX 800, BioTek, USA) using dichlorodihydrofluorescein diacetate (DCFH-DA), a vital fluorescent probe which enters to cells and is hydrolyzed to 2',7'-dichlorofluorescein (DCFH₂). Reaction with ROS forms the highly fluorescent dichlorofluorescein (DCF) which effluxes from the cells. The fluorescence intensity of DCF was measured by fluorescence plate reader at 485-nm excitation and 538-nm emission wave lengths, respectively. Results were communicated as fluorescence percentage of control cells [24].

Caspase 3 Activity Assay

The effects of ATO and morphine on caspase-3 activity in H9c2 cells were measured by colorimetric caspase-3 assay kit (Sigma). This assay is based on hydrolysis of peptide substrate (AC-DEVE-pNA) that is mediated by caspase-3 in a 96-well plate at 37 °C for 2 h. Absorbance of pNA is measured spectrophotometrically at 405-nm wavelength [25].

Cell-Based NF- κ B Phosphorylation Measurement

The effects of ATO and morphine on NF- κ B activation were assessed by an ELISA assay based on phosphorylated NF- κ B form to total ratio at 450 nm (CASE Kit, Super Array Bioscience, Frederick) as described with Janssen and Sen [26].

Analysis of Gene Expression by Real-Time Quantitative PCR

Fast Pure RNA Kit (Takara Bio, Inc., Otsu, Japan) was used to extract total RNA from the cultured cells. Changes in messenger RNA (mRNA) expression of desired genes were evaluated by real-time PCR after reverse transcription of 1 μ g RNA from each sample with Prime Script RT Reagent Kit (Takara Bio) according to the manufacturer's instructions. Quantitative real-time RT-PCR was done on a light cycler instrument (Roche Diagnostics, Mannheim, Germany) using SYBR Premix Ex Taq technology (Takara Bio). The PCR assay was performed in a final volume of 20 μ l containing 10 μ l of SYBR Green master mix, 2 μ l of cDNA samples, 0.5 μ l of each forward and reverse primers (10 pmol), and 7 μ l of nuclease-free water (Qiagen, Hilden, Germany). Thermal cycling environment involved an initial activation step for 30 s at 95 °C followed by 45 cycles including a denaturation step for 5 s at 95 °C and a combined annealing/extension step for 20 s at 60 °C. Melting curve investigation was applied to confirm whether all primers yield a single PCR product. Primers are mentioned in Table 1. Hypoxanthine

Table 1 Primer sequences for real-time RT-PCR experiments

Gene	Forward primer (5′–3′)	Reverse primer (3′–5′)
HPRT	TGGACAGGACTGAACGTCTTG	CCAGCAGGTCAGCAAAGAATTTA
PUMA	GACCTCAACGCACAGTACGAG	AGGAGTCCCATGATGAGATTGT
BAX	CGAGAGGTCTTTTCCGAGTG	GTGGGCGTCCCAAAGTAGG
Bcl-2	CGGTGGGGTCATGTGTGTG	CGGTTCAGGTACTCAGTCATCC
Survivin	CCAGATGACGACCCCATAGAG	TTGTTGGTTTCCTTTGCAATTTT
cIAP2	TCCTGGATAGTCTACTAACTGCC	GCTTCTTGAGAGAGTTTCTGAA
XIAP	ATAGTGCCACGCAGTCTACAA	AGATGGCCTGTCTAAGGCAAA
Bcl-XL	GAGCTGGTGGTTGACTTTCTC	AGATGGCCTGTCTAAGGCAAA
cIAP1	GTCCTCTGCGGAAGTGACTC	GGAAACTGGCGCTGGTATAA

phosphoribosyltransferase1 (HPRT1) was amplified as a normalizer, and fold adjust in expression of each target mRNA relative to HPRT1 was considered based on $2^{-\Delta\Delta C_t}$ relative expression formula [27].

Statistical Analysis

Data are expressed as mean \pm standard deviation (SD). All the experiments were carried out in triplicate. For statistical analysis, the Student's *t* test and one-way ANOVA were applied. In order to compare the groups, Dunnett's multiple-comparison test was used. *P* values less than 0.05 were considered significant.

Results

Morphine Antagonizes Inhibitory Effects of ATO on Viability in H9c2 Cells

The activity of complex II was assessed using MTT test after incubating H9c2 cells with different concentrations of ATO (0.5, 1, and 2 μ M). Figure 1 shows a significant decrease in the mitochondrial metabolism of MTT to formazan ($p < 0.05$) following treatment with ATO (0.5, 1, and 2 μ M) comparing to control group in a concentration-dependent manner. Also, pretreatment with morphine (1 μ M) before ATO treatment (4 h) significantly antagonized the inhibitory effects of ATO on viability of H9c2 cells ($P < 0.05$).

Morphine Reverses ATO-Induced ROS (H_2O_2) Formation in H9c2 Cells

As shown in Fig. 2, ATO (0.5–2 μ M) induced significant ROS (H_2O_2) formation in comparison with control group in a concentration-dependent manner. A substantial increase in mitochondrial ROS formation was observed in higher concentrations of ATO (2 μ M). On the other hand, pretreatment with

morphine (1 μ M) significantly attenuated ROS production induced by ATO in H9c2 cells ($P < 0.05$).

Morphine Antagonizes Inhibitory Effects of ATO on DNA Synthesis in H9c2 Cells

As shown in Fig. 3, using the BrdU cell incorporation assay to measure proliferation, the incorporation of BrdU in ATO-treated cells apparently affects the subsequent cell growth in H9c2 cells. Our results showed the inhibitory effect of ATO (0.5, 1, and 2 μ M) on DNA synthesis in concentration-dependent manner. On the other hand, morphine (1 μ M) could antagonize the suppressive effects of ATO in desired concentration on DNA synthesis in H9c2 cells.

Morphine Antagonizes ATO-Induced Caspase-3 Activation

As shown in Fig. 4, activity of caspase-3 enzyme (main mediator of apoptosis) was significantly increased (1.25–1.5-fold comparing to control) in H9c2 cells, following 48 h of exposure with ATO (1 and 2 μ M). However, lower concentration of ATO (0.5 μ M) did not significantly increase ROS generation compared to control mitochondria ($P > 0.05$). Significant decrease in the caspase-3 activity was observed following the treatment with morphine (1 μ M) in the incubation time in all of ATO treated groups ($P < 0.05$), suggesting the role of oxidative stress in mitochondrial permeability transition (MPT)-mediated caspase-3 activation and finally cytochrome c release.

Morphine Antagonizes with ATO-Induced Modulation of Expression of Apoptosis Markers

As shown in Fig. 5, exposure with ATO (2 μ M) for 48 h significantly increased expression of apoptotic genes *BAX* and *PUMA* compared to control groups ($P < 0.001$). Furthermore, ATO significantly decreased expression of anti-apoptotic genes *BCL2*, *survivin*, *cIAP1*, *cIAP2*, *XIAP*,




Fig. 1 MTT assay was applied to estimate the proliferative capacity of H9c2 cells over 72 h of treatment with escalating concentrations of ATO (a) and ATO plus morphine (1 μM) (b). Data are expressed as mean ± SEM and were analyzed by one-way ANOVA and Tukey's post hoc test. * $P < 0.05$, ** $P < 0.01$, and *** $P < 0.001$ compared to control group

and *BCL-XL* in comparison with control groups ($P < 0.05$ and $P < 0.01$). In addition, our results showed that morphine significantly reversed the decrease in expression of apoptotic genes *BAX* and *PUMA* ($P < 0.001$) and also increased




Fig. 2 The level of ROS generation in H9c2 cells exposed to different concentrations of ATO and ATO plus morphine (1 μM) for 48 h. Data are expressed as mean ± SEM and were analyzed by one-way ANOVA and Tukey's post hoc test. # $P < 0.05$, ## $P < 0.01$, and ### $P < 0.001$ compared to control group. ** $P < 0.01$ and *** $P < 0.001$ compared to ATO-related exposed groups




Fig. 3 The effects of enhancing doses of ATO (a) and ATO plus morphine (1 μM) (b) on DNA synthesis in H9c2 cells over 72 h of treatment. Data are expressed as mean ± SEM and were analyzed by one-way ANOVA and Tukey's post hoc test. * $P < 0.05$, ** $P < 0.01$, and *** $P < 0.001$ compared to control group

expression of anti-apoptotic genes *BCL2* and *survivin* in comparison with control group ($P < 0.05$ and $P < 0.01$, respectively).

Morphine Reverses ATO-Mediated Suppression of NF-κB Activation in H9c2 Cells

For determining the relationship between inhibition of NF-κB and ATO-induced apoptosis, we used different concentration of ATO (0.5–2 μM) and pretreatment with morphine (1 μM) in H9c2 cell line. As shown in Fig. 6, NF-κB activity significantly decreased following higher concentration of ATO (1 and 2 μM) compared to control group ($P < 0.05$). Furthermore, pretreatment with morphine (1 μM) significantly reversed ATO-mediated suppression of NF-κB activation in H9c2 cells after 48 h.

Discussion

Morphine, as an analgesic drug, has been reported to have antioxidant and anti-apoptotic effects including ROS scavenger capacity, inhibition of NADPH oxidase activity, and increasing of glutathione levels in neuronal and heart cells




Fig. 4 The caspase 3 activity in H9c2 cells exposed to increasing doses of ATO and ATO plus morphine (1 μM) for 48 h. Data are expressed as mean ± SEM and were analyzed by one-way ANOVA and Tukey's post hoc test. ###*P* < 0.001 compared to control group. ****P* < 0.001 compared to ATO-related exposed groups

[28–31]. Based on previous studies, the inhibitory effect of morphine on glutamate-induced astrocyte toxicity is related to intracellular redox reactions which are not prevented by naloxone, suggesting that opioids have receptor-independent mechanisms [32]. Moreover, there are several reports indicating that opioid agonists exert strong protective effects on ischemia-reperfusion conditions in the heart [33]. It has been reported that activation of opioid receptors induces hibernation-like states that increase organ stress resistance via induction of low energy consumption and activation of ATP-sensitive K^+ channels [34, 35]. Besides, morphine induces a preconditioning effect on C8-B4, a microglial cell line via decreasing of LDH release, an indicator of cell toxicity, as well as decreasing the release of TNF-α [35, 36]. Our results




Fig. 5 The expression of apoptotic and anti-apoptotic genes in H9c2 cells exposed to ATO (2 μM) and ATO plus morphine (1 μM) for 48 h. Data are expressed as mean ± SEM and were analyzed by one-way ANOVA and Tukey's post hoc test. **P* < 0.05, ***P* < 0.01, and ****P* < 0.001 compared to ATO-related exposed groups. #*P* < 0.05, ##*P* < 0.01, and ###*P* < 0.001 compared to control groups




Fig. 6 The NF-κB activity in H9c2 cells exposed to escalating concentrations of ATO and ATO plus morphine (1 μM) for 48 h. Data are expressed as mean ± SEM and were analyzed by one-way ANOVA and Tukey's post hoc test. #*P* < 0.05 and ##*P* < 0.01 compared to control group. ****P* < 0.001 compared to ATO-related exposed groups

are corroborated with evidence indicating that protective role of morphine in ATO-induced oxidative stress is associated with changes in antioxidant activity (GSH level and superoxide dismutase activity) and inhibition of generation of superoxide anion radicals [28, 37].

The concentration ranges of ATO (0.5–2 μM) and morphine (1 μM) were selected on the basis of a series of pilot studies in our laboratory [12, 38, 39]. Although the concentrations of ATO used in this study might seem relatively high, in vitro research works in mechanistic toxicology simulate chronic/low concentration, problems with acute/high-concentration condition in cell lines which cannot be kept alive or operate more than maximum 3–4 weeks following treatment. Obtaining statistically valid results and determination of toxicity mechanisms from in vitro or in vivo test (in small groups) require the administration of relatively large doses so that the effect will occur frequently enough to be detected [40].

Several lines of research have revealed that ATO is used as an anti-tumor drug, especially in treatment of APL; hematopoietic malignancies; and solid tumors such as liver, prostate, breast, and gastric cancers [41–44]. However, there are reported side effects of ATO in heart including T-wave and A-V block [45, 46].

Our data confirmed decreased activity of succinate dehydrogenase (SDH), a constitutive molecule of complex II in mitochondrial electron transfer chain through reduction of MTT to formazan [8]. In addition, it was also found that ATO significantly inhibited mitochondrial complex II activity in a concentration-dependent manner (*P* < 0.05) in H9c2 cells that indicates the disturbance in electron chain transfer. Also, the present data showed that pretreatment with morphine before ATO effectively reduced complex II activity in cardiomyocytes. Evidence suggests that main site of

MTT reduction is mitochondrial complex II and activity of this complex is responsible for most cellular reduction capacity and criteria for evaluation of electron transfer chain [47].

Besides, morphine antagonized the suppressive effects of ATO on DNA synthesis, explaining the increased resistance of cardiomyocytes against ATO-induced apoptosis. In addition, we found a significant increase in ROS generation in H9c2 cells following exposure with ATO (0.5–2 μM). Previous studies show that mitochondrial respiratory chain complex is the main source of ROS production [48] and impairment in any component of respiratory chain could cause mitochondrial dysfunction followed by oxidative stress and cell injury [49], which further causes tissue damage and organ dysfunction.

Also, increasing of ROS production leads to MPT pore opening and release of cytochrome c that triggers caspase-3 activation as the main initiator of apoptotic pathways [50]. Therefore, the caspase-3 activity was measured in H9c2 cells when incubated with ATO and morphine. Similarly, a recent in vitro study on cardiac cells showed that exposure to morphine decreased caspase-3 activation in doxorubicin-induced oxidative stress via mitochondrial dysfunction [51–54]. It has been suggested that ATO causes cardiac toxicity similar to doxorubicin via intrinsic and extrinsic pathways of apoptosis which affected mitochondrial damage, and this study suggested that morphine could reverse ATO-induced cytotoxicity. It seems that the protective effect of morphine against ATO was partly mediated via inhibiting of MPT pore opening [55].

In tumor cells, constitutive NF- κB activity is responsible for proliferation and to protect cells from apoptosis and drug resistance [56]. Previous studies have shown that ATO suppresses NF- κB pathway which has a key role in tumorigenesis via induction of transcriptional level in apoptotic genes such as *PUMA* and *BAX* [10, 11]. In the present study, our data showed that morphine increased the level of NF- κB , suggesting that morphine is able to induce a decrease in expression of apoptotic genes, an increase in the level of anti-apoptotic markers, and a decrease in caspase-3 activity in ATO-treated cells.

Conclusion

Due to the fact that morphine exerts protective effects on ATO-exposed cardiomyocytes, its utility can be a new strategy for protection and/or management of cardiac toxicity in patients who receive ATO as an anti-cancer treatment.

Compliance with Ethical Standards

Conflict of Interest The authors have no conflicts of interest to declare regarding the study described in this article and preparation of the article.

References

- Huang X, Maimaiti X, Huang C, Zhang L, Li Z, Chen Z, Gao X, Chen T (2014) Synergistic effects of arsenic trioxide combined with ascorbic acid in human osteosarcoma MG-63 cells: a systems biology analysis. *Eur Rev Med Pharmacol Sci* 18(24):3877–3888
- Beauchamp EM, Serrano R, Platanias LC (2014) Regulatory effects of arsenic on cellular signaling pathways: biological effects and therapeutic implications. In: *Nuclear Signaling Pathways and Targeting Transcription in Cancer*. Springer 107–119
- Mannis G, Logan A, Leavitt A, Yanada M, Hwang J, Olin R, Damon L, Andreadis C, Ai W, Gaensler K (2015) Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis. *Bone Marrow Transplant* 50(1):40–44
- Wen X, Li D, Zhang Y, Liu S, Ghali L, Iles RK (2012) Arsenic trioxide induces cervical cancer apoptosis, but specifically targets human papillomavirus-infected cell populations. *Anticancer Drugs* 23(3):280–287
- Park WH, Kim SH (2012) Arsenic trioxide induces human pulmonary fibroblast cell death via the regulation of Bcl-2 family and caspase-8. *Mol Biol Rep* 39(4):4311–4318
- Selvaraj V, Armistead MY, Cohenford M, Murray E (2013) Arsenic trioxide (As_2O_3) induces apoptosis and necrosis mediated cell death through mitochondrial membrane potential damage and elevated production of reactive oxygen species in PLHC-1 fish cell line. *Chemosphere* 90(3):1201–1209
- Selvaraj V, Armistead MY, Cohenford M, Murray E (2013) Arsenic trioxide (As_2O_3) induces apoptosis and necrosis mediated cell death through mitochondrial membrane potential damage and elevated production of reactive oxygen species in PLHC-1 fish cell line. *Chemosphere*
- Hosseini M-J, Shaki F, Ghazi-Khansari M, Pourahmad J (2013) Toxicity of arsenic (III) on isolated liver mitochondria: a new mechanistic approach. *Iran J Pharm Res: IJPR* 12(Suppl):121
- Hassani S, Yaghoubi H, Khosrokhavar R, Jafarian I, Mashayekhi V, Hosseini M-J, Shahraki J (2015) Mechanistic view for toxic effects of arsenic on isolated rat kidney and brain mitochondria. *Biologia* 70(5):683–689
- Ray RM, Bhattacharya S, Johnson LR (2011) Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73 and E2F1-mediated expression of PUMA and Siva-1. *Apoptosis* 16(1):35–44
- Melino G, De Laurenzi V, Vousden KH (2002) p73: friend or foe in tumorigenesis. *Nat Rev Cancer* 2(8):605–615
- Momeny M, Zakidizaji M, Ghasemi R, Dehpour AR, Rahimi_Balaei M, Abdolazimi Y, Ghavamzadeh A, Alimoghaddam K, Ghaffari SH (2010) Arsenic trioxide induces apoptosis in NB-4, an acute promyelocytic leukemia cell line, through up-regulation of p73 via suppression of nuclear factor kappa B-mediated inhibition of p73 transcription and prevention of NF- κB -mediated induction of XIAP, cIAP2, BCL-XL and survivin. *Med Oncol* 27(3):833–842
- Ben-Neriah Y, Karin M (2011) Inflammation meets cancer, with NF- κB as the matchmaker. *Nat Immunol* 12(8):715–723
- Mei Y, Zheng Y, Wang H, Gao J, Liu D, Zhao Y, Zhang Z (2011) Arsenic trioxide induces apoptosis of fibroblast-like synoviocytes and represents antiarthritis effect in experimental model of rheumatoid arthritis. *J Rheumatol* 38(1):36–43
- Carter BZ, Andreeff M (2015) IAP family of proteins as therapeutic targets for acute myeloid leukemia. In: *Targeted Therapy of Acute Myeloid Leukemia*. Springer 95–121
- Karin M, Cao Y, Greten FR, Li Z-W (2002) NF- κB in cancer: from innocent bystander to major culprit. *Nat Rev Cancer* 2(4):301–310
- Niu C, Yan H, Yu T, Sun H-P, Liu J-X, Li X-S, Wu W, Zhang F-Q, Chen Y, Zhou L (1999) Studies on treatment of acute promyelocytic

- leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. *Blood* 94(10):3315–3324
18. Naito K, Kobayashi M, Sahara N, Shigeno K, Nakamura S, Shinjo K, dasu Tobita T, Takeshita A, Ohno R, Ohnishi K (2006) Two cases of acute promyelocytic leukemia complicated by torsade de pointes during arsenic trioxide therapy. *Int J Hematol* 83(4):318–323
 19. Nabhan C, Mehta J, Tallman M (2001) Mini-review—the role of bone marrow transplantation in acute promyelocytic leukemia. *Bone Marrow Transplant* 28(3):219–226
 20. Weinberg SL (1960) The electrocardiogram in acute arsenic poisoning. *Am Heart J* 60(6):971–975
 21. Schwartz PJ, Malliani A (1975) Electrical alternation of the T-wave: clinical and experimental evidence of its relationship with the sympathetic nervous system and with the long QT syndrome. *Am Heart J* 89(1):45–50
 22. Hwang J-T, Kwon DY, Park OJ, Kim MS (2008) Resveratrol protects ROS-induced cell death by activating AMPK in H9c2 cardiac muscle cells. *Genes Nutr* 2(4):323–326
 23. Manna P, Sinha M, Sil PC (2008) Arsenic-induced oxidative myocardial injury: protective role of arjunolic acid. *Arch Toxicol* 82(3):137–149
 24. Elyasi L, Eftekhari-Vaghefi SH, Esmaeili-Mahani S (2014) Morphine protects SH-SY5Y human neuroblastoma cells against 6-hydroxydopamine-induced cell damage: involvement of anti-oxidant, calcium blocking, and anti-apoptotic properties. *Rejuvenation Res* 17(3):255–263
 25. Sakahira H, Enari M, Nagata S (1998) Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. *Nature* 391(6662):96–99
 26. Janssen YM, Sen CK (1999) Nuclear factor κ B activity in response to oxidants and antioxidants. *Methods Enzymol* 300:363–374
 27. Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative CT method. *Nat Protoc* 3(6):1101–1108
 28. Gülçın I, Beydemir Ş, Alici HA, Elmastaş M, Büyükköroğlu ME (2004) In vitro antioxidant properties of morphine. *Pharmacol Res* 49(1):59–66
 29. Qian L, Tan KS, Wei S-J, Wu H-M, Xu Z, Wilson B, Lu R-B, Hong J-S, Flood PM (2007) Microglia-mediated neurotoxicity is inhibited by morphine through an opioid receptor-independent reduction of NADPH oxidase activity. *J Immunol* 179(2):1198–1209
 30. Feng Y, Lu Y, Lin X, Gao Y, Zhao Q, Li W, Wang R (2008) Endomorphins and morphine limit anoxia-reoxygenation-induced brain mitochondrial dysfunction in the mouse. *Life Sci* 82(13):752–763
 31. Rostami F, Oryan S, Ahmadiani A, Dargahi L (2012) Morphine preconditioning protects against LPS-induced neuroinflammation and memory deficit. *J Mol Neurosci* 48(1):22–34
 32. Lee J, Kim MS, Park C, Jung EB, Choi DH, Kim TY, Moon SK, Park R (2004) Morphine prevents glutamate-induced death of primary rat neonatal astrocytes through modulation of intracellular redox. *Immunopharmacol Immunotoxicol* 26(1):17–28
 33. Lemoine S, Zhu L, Massetti M, Gérard JL, Hanouz JL (2011) Continuous administration of remifentanyl and sufentanyl induces cardioprotection in human myocardium, in vitro. *Acta Anaesthesiol Scand* 55(6):758–764
 34. Kevelaitis E, Peynet J, Mouas C, Launay J-M, Menasché P (1999) Opening of potassium channels the common cardioprotective link between preconditioning and natural hibernation? *Circulation* 99(23):3079–3085
 35. Headrick JP, See Hoe LE, Du Toit EF, Peart JN (2015) Opioid receptors and cardioprotection—‘opioidergic conditioning’ of the heart. *Br J Pharmacol* 172(8):2026–2050
 36. Gwak M-S, Li L, Zuo Z (2010) Morphine preconditioning reduces lipopolysaccharide and interferon- γ -induced mouse microglial cell injury via δ 1 opioid receptor activation. *Neuroscience* 167(2):256–260
 37. Almeida MBD, Costa-Malaquias A, Nascimento JLM, Oliveira K, Herculano A, Crespo-López ME (2014) Therapeutic concentration of morphine reduces oxidative stress in glioma cell line. *Braz J Med Biol Res* 47(5):398–402
 38. Murugan NJ, Dotta BT, Karbowski LM, Persinger MA (2014) Conspicuous bursts of photon emissions in malignant cells cultures following injections of morphine: implications for cancer treatment. *Int J Curr Res* 6:10588–10592
 39. Hou W, Li H, Jiang W, Zhang C, McNutt MA, Li G (2015) Simian immunodeficiency virus impacts microRNA-16 mediated post-transcriptional regulation of mu opioid receptor in CEM x174 cells. *J Cell Biochem*
 40. Hosseini M-J, Shaki F, Ghazi-Khansari M, Pourahmad J (2014) Toxicity of copper on isolated liver mitochondria: impairment at complexes I, II, and IV leads to increased ROS production. *Cell Biochem Biophys* 70(1):367–381
 41. Miller WH, Schipper HM, Lee JS, Singer J, Waxman S (2002) Mechanisms of action of arsenic trioxide. *Cancer Res* 62(14):3893–3903
 42. Diepart C, Karroum O, Magat J, Feron O, Verrax J, Calderon PB, Grégoire V, Leveque P, Stockis J, Dauge N (2012) Arsenic trioxide treatment decreases the oxygen consumption rate of tumor cells and radiosensitizes solid tumors. *Cancer Res* 72(2):482–490
 43. Zhang X, Jia S, Yang S, Yang Y, Yang T, Yang Y (2012) Arsenic trioxide induces G2/M arrest in hepatocellular carcinoma cells by increasing the tumor suppressor PTEN expression. *J Cell Biochem* 113(11):3528–3535
 44. Wu J, Ji Z, Liu H, Liu Y, Han D, Shi C, Shi C, Wang C, Yang G, Chen X (2013) Arsenic trioxide depletes cancer stem-like cells and inhibits repopulation of neurosphere derived from glioblastoma by downregulation of Notch pathway. *Toxicol Lett* 220(1):61–69
 45. Mathews V, Desire S, George B, Lakshmi K, Rao J, Viswabandya A, Bajel A, Srivastava V, Srivastava A, Chandy M (2006) Hepatotoxicity profile of single agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia, its impact on clinical outcome and the effect of genetic polymorphisms on the incidence of hepatotoxicity. *Leukemia* 20(5):881
 46. Au W-Y, Kwong Y-L (2005) Frequent varicella zoster reactivation associated with therapeutic use of arsenic trioxide: portents of an old scourge. *J Am Acad Dermatol* 53(5):890–892
 47. Mashayekhi V, Tehrani KHME, Hashemzaei M, Tabrizian K, Shahraki J, Hosseini M (2015) Mechanistic approach for the toxic effects of perfluorooctanoic acid on isolated rat liver and brain mitochondria. *Hum Exp Toxicol*: 0960327114565492
 48. Eskandari M, Mashayekhi V, Aslani M, Hosseini MJ (2015) Toxicity of thallium on isolated rat liver mitochondria: the role of oxidative stress and MPT pore opening. *Environ Toxicol* 30(2):232–241
 49. Jafarian I, Eskandari MR, Mashayekhi V, Ahadpour M, Hosseini M-J (2013) Toxicity of valproic acid in isolated rat liver mitochondria. *Toxicol Mech Methods* 23(8):617–623
 50. Pourahmad J, Hosseini M-J (2012) Application of isolated mitochondria in toxicological and clinical studies. *Iran J Pharm Res: IJPR* 11(3):703
 51. Lin X, Li Q, Wang Y, Ju Y, Chi Z, Wang M, Liu J (2007) Morphine inhibits doxorubicin-induced reactive oxygen species generation and nuclear factor kappaB transcriptional activation in neuroblastoma SH-SY5Y cells. *Biochem J* 406:215–221
 52. Liu J-X, Zhou G-B, Chen S-J, Chen Z (2012) Arsenic compounds: revived ancient remedies in the fight against human malignancies. *Curr Opin Chem Biol* 16(1):92–98
 53. Taira N, Yamaguchi T, Kimura J, Lu Z-G, Fukuda S, Higashiyama S, Ono M, Yoshida K (2014) Induction of amphiregulin by p53

- promotes apoptosis via control of microRNA biogenesis in response to DNA damage. *Proc Natl Acad Sci* 111(2):717–722
54. Verma R, Vasu A, Saiyed AA (2004) Arsenic toxicity in mice and its possible amelioration. *J Environ Sci Amst* 16(3):447–453
55. Nazari A, Sadr SS, Faghihi M, Azizi Y, Hosseini M-J, Mobarra N, Tavakoli A, Imani A (2015) Vasopressin attenuates ischemia–reperfusion injury via reduction of oxidative stress and inhibition of mitochondrial permeability transition pore opening in rat hearts. *Eur J Pharmacol* 760:96–102
56. Mathas S, Lietz A, Janz M, Hinz M, Jundt F, Scheidereit C, Bommert K, Dörken B (2003) Inhibition of NF- κ B essentially contributes to arsenic-induced apoptosis. *Blood* 102(3):1028–1034